103 CARNEGIE CENTER DRIVE, SUITE 309, PRINCETON, NJ
Announces Completion of Strategic Review
Material disclosure
Announces Departure of Chief Financial Officer
Announces Departure of Chief Executive Officer
Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
Q3
Q2
Q1
FY 2022
FY 2021
Notice of Suspension of Duty to File Reports
Effectiveness Notice
SEC Form 25 - Delisting Notification
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Notice of Proposed Sale of Securities
Post-Effective Amendment to a Registration Statement for Depositary Shares
S-8 POS
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence